Why the study?
Hyperglycemia and pulmonary hypertension share common pathological pathways leading to vascular dysfunction, but their relationship and clinical implications required exploration to enable early detection and targeted therapeutics.
Hyperglycemia and pulmonary hypertension share common pathological pathways and clinical factors, highlighting the need for early detection and targeted therapeutics for at-risk individuals.
Shared pathways between hyperglycemia and PH suggest comorbidity vigilance; leaves open causal trials on integrated therapies.
Hyperglycemia and pulmonary hypertension (PH) share common pathological pathways that lead to vascular dysfunction and resultant cardiovascular complications. These shared pathologic pathways involve endothelial dysfunction, inflammation, oxidative stress, and hormonal imbalances. Individuals with hyperglycemia or pulmonary hypertension also possess shared clinical factors that contribute to increased morbidity from both diseases. This review aims to explore the relationship between PH and hyperglycemia, highlighting the mechanisms underlying their association and discussing the clinical implications. Understanding these common pathologic and clinical factors will enable early detection for those at-risk for complications from both diseases, paving the way for improved research and targeted therapeutics.
No takes yet. Share an insight, caveat, or question.
Bruck et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: